FLIPL and CrmA-transduced RMA-S cells establish tumors at a higher frequency than mock-transduced cellsa
| . | No. of Tumor Cells Injected . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| . | 105 . | 104 . | 103 . | 102 . | |||
| RMA | 100 (5/5) | 100 (10/10) | 86.6 (13/15) | 79.2 (19/24) | |||
| RMA-S mock | 80 (4/5) | 60 (6/10) | 40 (6/15) | 4 (1/24) | |||
| RMA-S FLIPL | 100 (5/5) | 90 (9/10) | 60 (9/15) | 26.9 (7/26) | |||
| RMA-S CrmA | 100 (5/5) | 70 (7/10) | 66.6 (10/15) | 33.3 (9/27) | |||
| . | No. of Tumor Cells Injected . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| . | 105 . | 104 . | 103 . | 102 . | |||
| RMA | 100 (5/5) | 100 (10/10) | 86.6 (13/15) | 79.2 (19/24) | |||
| RMA-S mock | 80 (4/5) | 60 (6/10) | 40 (6/15) | 4 (1/24) | |||
| RMA-S FLIPL | 100 (5/5) | 90 (9/10) | 60 (9/15) | 26.9 (7/26) | |||
| RMA-S CrmA | 100 (5/5) | 70 (7/10) | 66.6 (10/15) | 33.3 (9/27) | |||
The final percentage of tumor take is shown, along with the absolute number of mice raising tumors in each group. The results from the groups injected with RMA-S are not shown, as they were similar to those obtained with the mock-transduced RMA-S cells. All experiments were repeated at least twice with groups of 5–8 mice per cell type, except for the experiment in which 105 cells were injected that was only performed once. In all experiments, tumor appearance was not seen before day 10 after injection. Moreover, no mice that were tumor-free at day 34 developed any tumor throughout the rest of the experiment (8 wk).